<DOC>
	<DOCNO>NCT01467297</DOCNO>
	<brief_summary>40 outpatient exacerbation Chronic Obstructive Pulmonary Diseases ( COPD ) enrol multi-centre , open-label , randomise , pilot study . Two treatment compare , ceftidoren 200 mg bid 5 day levofloxacin 500 mg daily 7 day . Primary objective study evaluate effect treatment serum inflammatory biomarkers secondary objective evaluate clinical microbiological efficacy Test Of Cure visit ( TOC ) , DAY 7-10 ( end treatment ) . The study foresee 4 visit : Visit 1 ( enrolment , day 1 treatment ) ; Visit 2 ( day 2-4 ) ; Visit 3 ( Test Of Cure-TOC visit , day 7-10 end treatment ) , Visit 3 ( Late Post Therapy assessment , Day 28-30 ) . The primary parameter test efficacy study medication assessment speed reduction inflammatory parameter ( CRP , PCT KL6 ) . Every reduction 10 % take account . The comparison treatment perform visit 2 3 .</brief_summary>
	<brief_title>Ceftidoren Versus Levofloxacin Treatment Patients With Acute Exacerbations Chronic Bronchitis ( AECB )</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1 . Male female outpatient age 40 75 year limitation race . 2 . Patients diagnosis Acute Exacerbations Chronic Bronchitis* characterize presence follow three symptom , least two include purulence : increased dyspnoea ; increase sputum volume ; increase sputum purulence , confirm macroscopically investigator . Chronic bronchitis characterize cough excessive secretion mucus diagnose patient report production sputum day least three consecutive month 2 consecutive year ( American Thoracic Society 1995 ) . 3 . FEV1 &gt; 50 % predict value . 4 . Availability valid sputum specimen bronchopulmonary origin microbiological evaluation obtain either expectoration , suction , bronchoscopy bronchial lavage . Valid sample characterize &lt; 10 squamous epithelial cell &gt; 25 polymorph nuclear leucocyte per lowpower magnification 100x field ( Wilson 2004 ) . 5 . Negative chest radiography rule pneumonia active tuberculosis . 6 . Written inform consent trial sign dated patient accord local regulation , obtain prior activity relate trial . 1 . Hypersensitivity allergy antibacterial betalactams fluoroquinolones and/or component study medication . 2 . Underlying asthma . 3 . Systemic corticosteroid ( treatment since â‰¤ 2 week trial drug administration ) exclude , unless patient chronically treat ( treatment &gt; 2 week trial drug administration ) . Corticosteroid nasal spray administration allow first 3 day study drug administration . 4 . Childbearing potential pregnancy exclude pregnancy test urine ( HCG ) , lactation . 5 . History tendinopathy . 6 . Recent past history psychiatric illness epilepsy . 7 . Recent past history cardiac disease rhythm disorder clinically significant ECG abnormality . 8 . Latent known deficiency glucose6phosphate dehydrogenase activity . 9 . Known severe hepatic and/or renal insufficiency ( AST , ALT and/or creatinine level twice high Upper Laboratory Norm , ULN ) . Should laboratory data available treatment require , patient may conditionally enrol . 10 . Other low respiratory tract illness : severe bronchiectasis , cystic fibrosis , pulmonary malignancy . 11 . Concurrent infection /or neoplasm . 12 . Concomitant treatment hypoglycemic drug . 13 . Patients treatment fenbufen xanthine . Patients treat xanthine could however recruit plasma level monitor ; plasma level exceed concentration 1015 micrograms/ml , daily dosage xanthine lower Investigator ( Hendels 1983 ) ; 14 . Treatment antibiotic antibacterial within previous week 15 . Treatment experimental drug previous 4 week</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic bronchitis</keyword>
	<keyword>exacerbation</keyword>
	<keyword>treatment</keyword>
	<keyword>ceftidoren</keyword>
	<keyword>levofloxacin</keyword>
	<keyword>inflammation</keyword>
</DOC>